Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Separately, a Delaware jury in late October found that Masimo’s current products did not infringe any of Apple’s patents. The ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo Corp (MASI) reports robust healthcare revenue growth and improved margins, while navigating non-healthcare segment ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Young said Masimo is lowering corporate overhead costs, with cuts such as selling the corporate jet and reducing marketing expenses for products that aren't producing meaningful revenue and returns.

Masimo Corporation MASI delivered adjusted earnings per share (EPS) of 98 cents in the third quarter of 2024, up 30.7% year ...

Q3 2024 Earnings Call Transcript November 5, 2024 Masimo Corporation beats earnings expectations. Reported EPS is $0.98, expectations were $0.84. Operator: Ladies and gentlemen, good afternoon, and ...

"Apple primarily sought an injunction against Masimo's current products, and the jury's verdict is a victory for Masimo on that issue," said the healthtech company in its statement on the outcome.

Time magazine’s list of the 200 best inventions of 2024 includes products by two famous Orange County entrepreneurs ...